Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
At AstraZeneca, we aim to revolutionise antibody discovery by significantly reducing the time to reach a clinical candidate using world-class technology and advanced data & AI capabilities. The Biologics Discovery Platform Product Lead will build a multi-quarter product roadmap and strategy to deliver an excellent science user experience, partnering with R&D product owners and cross-functional teams that work in the earliest stages of Biologics discovery.
About Maxion
Maxion Therapeutics is a pioneering biotechnology company dedicated to developing groundbreaking biologic medicines for diseases with unmet needs, driven by ion channel and GPCR dysfunction. Our innovative KnotBody® technology empowers us to create potent, selective, and durable antibody therapeutics. This technology merges millions of years of cysteine-rich mini-protein ('Knottin') evolution with cutting-edge antibody engineering, addressing pivotal challenges in ion channel/GPCR drug discovery.
The Insights team is LifeArc’s central resource for analysing scientific, competitive and IP landscapes to support strategy, project selection and portfolio decisions. The team works closely with LifeArc Ventures and our Translational Challenges to analyse the potential of translational life science opportunities, informing decision making and ensuring LifeArc achieves maximum patient impact.
Royston, 3 February 2026.
Starting something new is hard – particularly within the fast-moving life science sector. Step forward Accelerate@Babraham, the Babraham Research Campus’ bio-incubator, founded out of a desire to support and nurture early-stage ventures; bringing to bear an unrivalled network of experts, mentors and investors and data-driven, comprehensive business analysis and support to equip these young enterprises with the skills, confidence and network connections to enable success.
bit.bio is an award-winning spinout from the University of Cambridge. Our breakthrough technology combines synthetic and stem cell biology for the precise, efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy. At bit.bio, we are passionate about engineering human cells that will enable the medicine of the future. To do this we need talented and curious people who want to make an impact on the future of science and therapeutics.
We are seeking a talented Computational Biologist to join the Genome Reference Informatics Team at Wellcome Sanger Institute on a 2 year contract contributing to the curation of genome assemblies to produce high quality chromosome-scale references.
About the Role:
LONDON, UK and COPENHAGEN, Denmark – February 2, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Kaffe Bueno and is pleased to announce the placement of Thomas Durhuus as Chief Executive Officer (CEO).
R&D Tax Credit Pre-Notification: A Critical Requirement for Innovators
Pre-notification is now a mandatory legislative requirement for certain companies intending to claim R&D tax credits. Introduced as part of HMRC’s reforms to the R&D tax relief regime, the rule applies to companies that are first-time claimants or those that have not made a relevant R&D tax credit claim in the previous three accounting periods. Affected companies must notify HMRC of their intention to claim within six months of the end of the relevant accounting period.